9926 Stock Overview
A biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Akeso, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$65.50 |
52 Week High | HK$72.55 |
52 Week Low | HK$26.45 |
Beta | 0.52 |
11 Month Change | 37.32% |
3 Month Change | 83.73% |
1 Year Change | 74.67% |
33 Year Change | 52.86% |
5 Year Change | n/a |
Change since IPO | 169.55% |
Recent News & Updates
Optimistic Investors Push Akeso, Inc. (HKG:9926) Shares Up 27% But Growth Is Lacking
Sep 09Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Aug 30Recent updates
Optimistic Investors Push Akeso, Inc. (HKG:9926) Shares Up 27% But Growth Is Lacking
Sep 09Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Aug 30Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment
Jun 24Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding
Jun 19Are Investors Undervaluing Akeso, Inc. (HKG:9926) By 43%?
May 31Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price
Apr 24We Think Akeso's (HKG:9926) Robust Earnings Are Conservative
Mar 25Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Mar 20Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price
Dec 28An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued
Nov 16Is Akeso (HKG:9926) Using Too Much Debt?
Oct 02The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts
Aug 31Is Akeso, Inc. (HKG:9926) Trading At A 40% Discount?
Jun 26There's Reason For Concern Over Akeso, Inc.'s (HKG:9926) Price
May 22Health Check: How Prudently Does Akeso (HKG:9926) Use Debt?
Apr 11Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%
Mar 21An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued
Mar 02Akeso, Inc.'s (HKG:9926) Intrinsic Value Is Potentially 95% Above Its Share Price
Nov 01Time To Worry? Analysts Are Downgrading Their Akeso, Inc. (HKG:9926) Outlook
Aug 28Shareholder Returns
9926 | HK Biotechs | HK Market | |
---|---|---|---|
7D | 6.2% | 0.2% | 4.1% |
1Y | 74.7% | -19.5% | 0.9% |
Return vs Industry: 9926 exceeded the Hong Kong Biotechs industry which returned -19.5% over the past year.
Return vs Market: 9926 exceeded the Hong Kong Market which returned 0.9% over the past year.
Price Volatility
9926 volatility | |
---|---|
9926 Average Weekly Movement | 9.8% |
Biotechs Industry Average Movement | 7.0% |
Market Average Movement | 6.3% |
10% most volatile stocks in HK Market | 13.3% |
10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 9926's share price has been volatile over the past 3 months.
Volatility Over Time: 9926's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 2,815 | Michelle Xia | www.akesobio.com |
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK105, a PD-1 monoclonal antibody to treat classic Hodgkin’s lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors.
Akeso, Inc. Fundamentals Summary
9926 fundamental statistics | |
---|---|
Market cap | HK$56.71b |
Earnings (TTM) | -HK$812.50m |
Revenue (TTM) | HK$2.07b |
27.4x
P/S Ratio-69.8x
P/E RatioIs 9926 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
9926 income statement (TTM) | |
---|---|
Revenue | CN¥1.87b |
Cost of Revenue | CN¥141.91m |
Gross Profit | CN¥1.73b |
Other Expenses | CN¥2.47b |
Earnings | -CN¥735.33m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.85 |
Gross Margin | 92.43% |
Net Profit Margin | -39.24% |
Debt/Equity Ratio | 64.2% |
How did 9926 perform over the long term?
See historical performance and comparison